Almirall saw no growth in patent filings and highest growth of 0.99% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and grants by 0.99%. GlobalData’s DataBook provides a comprehensive analysis of Almirall‘s patent filings and grants. Buy the databook here.
Smarter leaders trust GlobalData
Almirall has been focused on protecting inventions in European Patent Office(EPO) with one publication in Q2 2024
The European Patent Office(EPO) Patent Office dominates the patent filings with nearly 100% of filings. The European Patent Office(EPO), Spain(ES), and Poland(PL) patent Office are among the top ten patent offices where Almirall is filings its patents. Among the top granted patent authorities, Almirall has 50% of its grants in Spain(ES) and 50% in Poland(PL).
Roche and Johnson & Johnson could be the strongest competitors for Almirall
Chronic obstructive pulmonary disease (copd) related patents lead Almirall portfolio followed by asthma, and wounds
Almirall has highest number of patents in chronic obstructive pulmonary disease (copd) followed by asthma, wounds, bronchospasm, and emphysema.
For comprehensive analysis of Almirall's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData patents database covers bibliographic from all 100+ patenting authorities. All patents are tagged to 18+ industries and 300+ sub-sectors based on technology classification, keywords, and associated companies. They are also tagged to various industries themes (100+) and technology domains (1800+) of focus.
Patents database further disambiguates assignee names (13m names) and associate corporate tree hierarchy in current/point in time ownerships (320k entities). GlobalData sources content directly from national patent offices on a weekly basis.
